Company intelligence / Profile preview

Verndari

Sacramento, California, United Statesverndariinc.com ↗
Ownership
Private
Employees
~25
Development stage
Other
01

Overview

Verndari’s preclinical studies using the VaxiPatch™, a single-dose vaccine kit using intradermal microarray technology, have demonstrated thermostability and higher efficacy compared to traditional vaccine delivery. The main focus has been on infectious diseases, notably with an ongoing COVID-19 vaccine effort[1][3][5].

Therapeutic areas
Infectious Diseases
Modalities
VaccinemRNA-based drugsDevice
Industry
Biotech

Beyond the preview

Go deeper on Verndari.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verndari.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call